My notes

My positions

Up-to-date information about stocks, bonds, funds and cryptocurrencies. Quotes, information about dividends and payment history, reporting of companies for 10 years, comparison of companies with each other.

Company analysis {{ticker}} {{description}} includes quotes, information about dividends and payment history, reporting of companies for 10 years, comparison of companies with each other.

{{description}} Stock Dividend Date & History

This place looks empty

Benchmarks

 Outstanding nominal value as of the current date

Average price of a bond, in % of face value

The current yield indicates the ratio of the accrued coupon to the current market price of the bond. It can be used in cases where attachments are considered for a short period of time. In this situation, the change in the market price can sometimes be neglected.

Bond duration is a way of measuring how much bond prices are likely to change if and when interest rates move.

Effective yield to maturity. It considers both coupon income and profit/loss due to the difference between the purchase price and the repayment price. Effective yield shows the investor the return on invested funds with reinvested coupons and depreciation.

Listing level — stock exchange assessment of securities reliability.

The ratio of the annual coupon to the "dirty" price of the bond, including the accrued interest. This type of yield can be used in the case of short-term investments, when the investment horizon is within one coupon period.

Average purchase price of a bond, in % of face value

Up to 2 years - short-term, up to 5 years - mid-term, more than 5 years - long-term

Bond type - goverment, municipal or corporate

Coupon yield % per annum of nominal value (coupon amount per year/nominal value)

 Simple yield to maturity. It considers both coupon income and profit/loss due to the difference between the purchase price and the repayment price. Simple yield shows the investor the return on invested funds without reinvested coupons.

Stay updated with the latest market trends and discover new growth opportunities with our blog.

New and interesting articles

The fund expense ratio is the annual fee expressed as a percentage of a mutual fund or ETF's average assets, covering management, administrative, and other operational costs. It directly reduces investors' returns.

10 years

12 trailing months

1 day

1 month

1 year

3 months

5 years

6 months

1 week

all time

Choose a period

year to date

Full list of latest news and articles is available with our "Starter", "Investor" plans

Your {{name}} file was successfully downloaded and is ready to use.

✅ Download complete

Your {{name}} is on its way! If there's an issue, try again or check your browser settings.

⏳ Downloading in progress

How can we improve the "Report" feature? Tell us what changes would make it more helpful for you.

You recently tried our new "Report" feature. Was it helpful? Share your feedback!

Rate the "Report" Feature

Get the full picture of your investments — subscribe to Investor or Expert for deeper insights.

Expert

Investor

What's included:

🚀 Upgrade your plan to unlock full report

Subscription change

We will be happy to receive your feedback

Why did you decide to cancel your subscription?

Simple pricing, for

every investor

Unlock advanced analytics with Snowball Analytics comprehensive pricing plans. Tailored for individuals, startups, and enterprises, our packages offer valuable insights to propel your investment strategies forward

Explore Pricing Plans and Pricing Dividend Tracker at Snowball Analytics

Welcome to {{name}}

Take full control of your investments

"<0></0>" plan limits

Choose a plan and start making the most out of your investments today

Maximize your portfolio's potential by using all our features designed to help you stay on top of your financial goals

Couldn't apply this code

Yay, you've got your discount!

I have a discount code!

Would you like to have the same portfolio?

Plans & Pricing - Snowball Analytics

Start your journey to financial independence

Disable 2FA

Get your authenticator app

Recovery codes

Enable two-factor authentication

Password login required

These are the backup codes for the Snowball Analytics account. Store them securely and keep them secret. Each code can only be used once.

Recovery codes can be used for authorization if you do not have access to your device.

Effective protection against hacking: in order to log in, you should enter a one-time code. If you're using external login (via Google, Apple) please enable 2FA there.

Two-Factor Authentication (2FA)

Get codes from an authentication app on your mobile device (ex. Google Authenticator, Authy, ...).

Login via Authentication app

Something went wrong

You have unsubscribed successfully

Unsubscribe from all emails

An email will be send to you with instructions on how to change your password, please check your email.

Delete my account

Account removal

You can cancel anytime but it will be active until the end of the paid period.

Our service functions on the basis of subscriptions. You can choose an annual or monthly subscription type. The fee will be charged once a year or a month, respectively.

🎉 Success!

Oops, the payment has failed

Subscription renewal

The payment history to your account is displayed here

All payments of your users and your remuneration are displayed here

Post the link to the Snowball Analytics on your blog or publish it on social networks

for the first two years since the user's registration, after that your remuneration will be

for the first two years since the user's registration

Terms of our partner program

All users who have been registered using your referral link are displayed here

Post your personal link to Snowball Analytics on your blog or social networks

Registered users are eligible for a 10% discount for the next purchase

You will receive 40% from every payment in first two years

Please write us an email to receive more information:

Earn with the Snowball Analytics

You can manage your subscription directly in App Store or you can cancel it there and subscibe using our native subscription plans.

Your subsciption works via Apple App Store.

Your subscription is cancelled. Subscribe to take advantage of all the benefits {{app}}

Your subscription is expired. Subscribe to keep receiving the benefits {{app}}

{{portfoliosCount}} portfolio, {{assetsCount}} assets

{{portfoliosCount}} number of portfolios, {{assetsCount}} amount of assets

{{portfoliosCount}} of your portfolio, {{assetsCount}} assets count

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Beigene Ltd

Frequently asked questions

What sector does Beigene Ltd (6160) operate in?

What is Beigene Ltd (6160) current stock price?

What is Beigene Ltd (6160) current market capitalization?

What is Beigene Ltd (6160) Earnings Per Share (EPS)?

Does Beigene Ltd (6160) pay dividends?

When is Beigene Ltd (6160) next earnings report?

What is Beigene Ltd (6160) beta (volatility) score?